AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (LSE:AZN) has received EU approval for the first new drug in over a decade for people with systemic lupus erythematosus (SLE). The disease occurs when the body's own immune system attacks tissue and organs.

AstraZeneca EU wins approval for the first drug in more than a decade for lupus

Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed metastatic, castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations. The Lynparza combination pared down that risk by 34% over Zytiga alone, according to phase 3 data released at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Why Are AstraZeneca Shares Trading Higher Today

London stocks rebounded on Tuesday, lifted by gains for AstraZeneca, though held back by losses for energy companies as oil prices fell amid positive headlines on the Ukraine-Russia crisis.

London Markets: London stocks join global bounce, with AstraZeneca leading on positive drug news

Pfizer

AstraZeneca and Pfizer are both table-pounding buys right now.

2 Dirt Cheap Dividend Stocks to Buy as a Hedge Against Market Volatility

AstraZeneca PLC (LSE:AZN)'s cancer drug used in combination with a common hormone therapy prolonged the life of end-stage prostate cancer treatments by eight months compared with the current treatment, according to the clinical trial's lead investigator. Lynparza (also known as olaparib) paired with abiraterone reduced the risk of disease progression by 34% versus the standard of care, which is abiraterone on its own.

AstraZeneca drug could help prolong life of terminally ill prostate cancer patients

BOGOTA, Colombia , Feb. 14, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. and AstraZeneca Colombia S.A.S.

Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in Colombia

AstraZeneca PLC (AZN) CEO Pascal Soriot on Q4 2021 Results - Earning Call Transcript

Shares of AstraZeneca plc (NASDAQ: AZN) are up 3.5% this morning on a significant YoY increase in Q4 revenue. Charges related to the Alexion acquisition, however, pushed it into a quarterly loss.

AstraZeneca reports Q4 results: ‘we're facing challenges in China'

AstraZeneca (AZN) surpasses fourth-quarter estimates for both revenues and earnings. The company issues 2022 guidance

AstraZeneca (AZN) Q4 Earnings Beat, COVID Vaccine Drives Sales

Since the acquisition of Alexion was completed, we were watching AstraZeneca from the sidelines. Holding but not taking any further action. Q4/FY 2021 earnings are marking a turning point for the company, for its future, for its dividend, and (consequently) for us. This has been nothing short of a superb quarter/year.

AstraZeneca Is Looking As Polished As A New Aston Martin

The drugmaker forecasts a high teens percentage increase in total revenue in 2022

AstraZeneca Stock Rises Because It Sees More Sales in 2022

Unilever

AstraZeneca helped nudge U.K. blue chips higher Thursday as the pharma giant showed how its acquisition of Alexion will push profits higher.

London Markets: AstraZeneca buoys FTSE 100 while Unilever slips on margin guidance

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time.

AstraZeneca sees $4B in COVID-19 vaccine sales

AstraZeneca Plc's AZN total revenue jumped 63% Y/Y to $12.01 billion in Q4 FY21 on a constant-currency basis, beating the consensus of $10.96 billion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21

AstraZeneca forecasts a high teens percentage increase in total revenue in 2022

AstraZeneca Sees Higher 2022 Sales. The Stock Is Rising.

Astrazeneca said global interest in government purchase agreements for its COVID-19 vaccine was driven by strong demand in Latin America, the Middle East and Asia, even as aggregate global demand this year will fall.

AstraZeneca says COVID vaccine demand high in Latam, Middle East, Asia

Alexion Pharma

AstraZeneca PLC (LSE:AZN) said five new drugs had taken on blockbuster status last year generating over US$1bn in revenues each as delivered a strong financial performance, boosted by the US$39bn takeover of Alexion Pharmaceuticals (NASDAQ:ALXN). Total revenues for 2021 were US$37.4mln, up 41%, while core earnings rose 32% to US$5.29 per share.

AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet

What now for AstraZeneca?  Coming the day after GSK, its former larger rival, AstraZeneca PLC reports following the closure of its Alexion acquisition halfway through last year.

AstraZeneca looks beyond Covid, US inflation and Unilever under pressure: Thursday's agenda

GlaxoSmithKline

If you are invested in AstraZeneca PLC (LSE:AZN), please look away now. For, the latest results statement from Pfizer has revealed its Covid jab and sales of a new antiviral will generate US$54bn in revenues this year after the American giant raked in US$37bn from mass inoculation programmes in 2021.

Will Pfizer's success push AstraZeneca and GlaxoSmithKline investors over the edge?

Second Sight Medical Products

Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction.  Second Sight Medical develops implantable visual prosthetics.

Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical

An Oxford University professor has reignited the row over AstraZeneca PLC (LSE:AZN)'s covid vaccine by claiming the criticism the jab received might have cost hundreds of thousands of lives. Sir John Bell, who worked on the vaccine's development, told the BBC that “Bad behaviour from scientists and from politicians has probably killed hundreds of thousands of people – and that they cannot be proud of.

AstraZeneca Covid jab criticism cost 'hundreds of thousands' of lives claims professor

Adicet Bio, Inc.

Amgen

These companies' share prices could rise in the short term, but their long-term opportunities are even better.

3 Biotech Stocks That Could Make You Richer in February (and Beyond)

Arch Resources

Axalta Coating Systems

ARCH, AZN, and AXTA have been added to the Zacks Rank #5 (Strong Sell) List on February 4, 2022

New Strong Sell Stocks for February 4th

AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences

Taiwan Semiconductor Manufacturing

XPeng

Global stocks that are worth holding for the long-term for a well diversified portfolio. High growth global stocks with strong fundamentals.

News for AstraZeneca Stock (AZN)